IQVIA Holdings Inc. (NYSE:IQV) Position Boosted by Sendero Wealth Management LLC

Sendero Wealth Management LLC boosted its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 16.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,486 shares of the medical research company's stock after buying an additional 7,265 shares during the period. IQVIA makes up about 1.3% of Sendero Wealth Management LLC's holdings, making the stock its 17th biggest position. Sendero Wealth Management LLC's holdings in IQVIA were worth $9,253,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of IQV. Whipplewood Advisors LLC increased its stake in shares of IQVIA by 7,142.2% during the first quarter. Whipplewood Advisors LLC now owns 3,259 shares of the medical research company's stock worth $575,000 after acquiring an additional 3,214 shares during the period. ST Germain D J Co. Inc. increased its position in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after purchasing an additional 76 shares during the period. Merit Financial Group LLC raised its stake in shares of IQVIA by 59.4% during the 1st quarter. Merit Financial Group LLC now owns 6,845 shares of the medical research company's stock worth $1,207,000 after buying an additional 2,552 shares in the last quarter. NBC Securities Inc. boosted its stake in shares of IQVIA by 352,600.0% in the first quarter. NBC Securities Inc. now owns 3,527 shares of the medical research company's stock valued at $621,000 after buying an additional 3,526 shares in the last quarter. Finally, American National Bank & Trust acquired a new position in IQVIA during the first quarter worth $26,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have commented on IQV. Truist Financial decreased their target price on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research report on Thursday, April 10th. Robert W. Baird dropped their price objective on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a report on Monday, February 10th. Finally, HSBC downgraded IQVIA from a "buy" rating to a "hold" rating and reduced their price objective for the company from $260.00 to $160.00 in a research report on Friday, April 25th. Eight analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $226.32.

IQVIA Stock Down 0.5%

NYSE:IQV traded down $0.68 during trading hours on Thursday, hitting $147.22. The stock had a trading volume of 3,264,210 shares, compared to its average volume of 1,590,588. The company has a market cap of $25.47 billion, a PE ratio of 19.63, a price-to-earnings-growth ratio of 1.99 and a beta of 1.28. The business has a 50 day simple moving average of $148.65 and a two-hundred day simple moving average of $179.70. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. The firm had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The firm's quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.54 EPS. Analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.